Skip to Main Content

Paper Details

Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.
Eur Urol
4
2021
Author NameAffiliation
Gerhardt AttardUniversity College London Cancer Institute
  • 1 - 1

Datasets

Release 1.2